3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
3
Active not recruiting
2
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Interventions
Radiotherapy
9
Cisplatin
9
Paclitaxel
6
Carboplatin
6
Radiation
3
Biopsy
3
Bevacizumab
3
balstilimab
2
Topotecan
2
Taxes
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Colposcopy
2
Brachytherapy
2
tislelizumab
1
spartalizumab
1
sitravatinib
1
rucaparib
1
pazopanib
1
infigratinib
1
fludarabine
1
bemarituzumab
1
atezolizumab
1
aldesleukin
1
Watchful Waiting
1
Vinorelbine
1
Vaginal Smears
1
Ultrasonography
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Uterine Cervical Neoplasms
×
tislelizumab
×
Clear all
NCT05614453
2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn